Pfizer cancels Neurocrine deal after delay of insomnia drug

06/22/2006 |

A week after Neurocrine Biosciences revealed a need for more clinical trials for its long-acting Indiplon, Pfizer said it is canceling its agreement to develop and market the insomnia drug. Pfizer had seen the drug as its entry in the competition against Ambien CR by Sanofi-Aventis and Lunesta by Sepracor.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA